Measures Plasminogen Activator Inhibitor type-1 (PAI-1) activity in human plasma.
As a primary regulator of fibrinolysis, PAI-1 is found in a number of tissues and cell types including macrophages/monocytes, hepatocytes, vascular endothelia, adipose tissue of the heart and lungs and in platelets. Levels of PAI-1 in plasma are associated with various thrombotic and fibrinolytic complications. Deficiency of PAI-1 activity is associated with bleeding disorders wherein routine hemostatic screening tests are normal. High levels of PAI-1 activity are found in patients suffering from myocardial infarction, hemolytic uremic syndrome and stroke.
The assay is a two-stage colorimetric assay. The first stage involves incubating samples with a known amount of tPA, allowing PAI-1 in the sample to react with tPA. In the second stage, the residual tPA activity converts plasminogen to plasmin, which in turn hydrolyzes a plasmin chromogenic substrate, SPECTROZYME® PL. PAI-1 in the plasma is determined as the difference between the amount of tPA added and the amount of tPA recovered.
Note, not registered with Health Canada
|PRODUCT NAME||REF||# of Tests|
|SPECTROLYSE® PAI-1 Activity Assay||101201||60|